Loading...
Adjuvant chemotherapy after resection of pancreatic cancer — which has evolved from single-agent gemcitabine or single-agent 5-FU to the combination of gemcitabine and capecitabine, and more recently FOLFIRINOX — has become the standard of care, after phase 3 trial results showed a survival benefit associated with this approach (e.g., NEJM JW Oncol Hematol Mar 2019 and N Engl J Med 2018; 379:2395, and NEJM JW Oncol Hematol Apr 2021 and JAMA Oncol 2021; 7:421). However, patients aged 80 and older were underrepresented in the trials, and thus, the benefit for these patients is uncertain.
To further examine the efficacy of adjuvant therapy for older pancreatic cancer patients, investigators now report results of a retrospective cohort study eva…